AlerSense Announces $1 Million Private Placement

By: AlerSense, Inc
Spread the Word
Listed Under

* Asthma Allergy COPD

* Health

* Burlingame - California - US

BURLINGAME, Calif. - July 1, 2016 - PRLog -- AlerSense Incorporated, a healthcare company focused on developing intelligent air sensors that alert those suffering from Allergies, Asthma, and COPD to dangerous changes in air quality, announced today a $1 million private placement exclusively to accredited investors.

The AlerSenseTM Smart Air Quality Sensor for Allergy, Asthma and COPD detects indoor air quality constituents, which may act as 'triggers' for people suffering from asthma, allergies, COPD and other respiratory ailments. These household triggers may include dust, pollen, mold spores, airborne dust mite allergens and chemicals or toxins in the air. Many people with respiratory issues are affected by these pollutants, and may also be unaware of their specific triggers, making it difficult for them to predict impending issues.

The device in addition to allergens and other particles also measures the temperature and humidity of the environment. Warnings are sent to the cloud for analyzation and then to the AlerSensetm smartphone app. This data, in combination with user input regarding issues or attacks, makes the system 'smarter' and continually self-adjusts to provide a more effective outcome. The initial designs are intended for home, office, schools or hotels.

Skip Sanzeri, AlerSensetm Founder and Chief Executive Officer stated, "We designed the system so it can be customized for each family member, and each room of the house. With user feedback, the system gets really smart."

In the United States and Canada, the appliance will be available this summer at a price of $249.

The Company will be using the proceeds from the Financing for branding, manufacturing expansion, product development, and management recruitment.

As part of the Financing, AlerSensetm is offering 1,666,667 shares of Series Seed Preferred Stock at $.60 a share with a minimum purchase of 20,000 shares.  The offering is only to accredited investors.

Maxwell Financial Services LLC, an Investment Bank specializing in Reg D 506(c) and Reg A+ private placements has been retained as the placement agent.

The securities sold in the Financing have not been registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements.

This notice is issued pursuant to Rule 135c under the Securities Act and does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such   state.

Any offering of the securities under the resale registration statement will only be using a prospectus.

About AlerSensetm, Inc.

AlerSensetm, Inc. is a privately held company based in Burlingame, California that develops, manufactures, and markets intelligent air sensor devices.  The products deliver warning messages to the smartphones of those afflicted with allergies, asthma, and COPD. For more information, visit our website at

Forward-Looking Statements

Certain statements contained in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent AlerSensetm's expectations or beliefs concerning future events, and it is possible that the results described in this news release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of AlerSensetm's control, which could cause actual results to differ materially from the results discussed in the forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, AlerSensetm does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for AlerSensetm to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements found in our filings with the SEC, including the prospectus filed with the SEC in connection with our initial public offering. The risk factors and other factors noted in our SEC filings could cause our actual results to differ materially from those contained in any forward-looking statement.

John White

Maxwell Financial Services LLC

(847) 867-5911

Source: AlerSensetm

Securities offered through Growth Capital Services (, member FINRA (, SIPC 582 Market Street, Suite 300, San Francisco, CA 94104. Please refer to FINRA BROKER CHECK ( for information about Maxwell Financial Services LLC and Growth Capital Services.

Skip Sanzeri AlerSense, Inc.
(650) 504-0465
Email:*** Email Verified
Tags:Asthma Allergy COPD
Location:Burlingame - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
AlerSense, Incorporated News
Most Viewed
Daily News

Like PRLog?
Click to Share